Pia M. Challita-Eid
YOU?
Author Swipe
View article: Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer Open
Here, we report the development of an antibody–drug conjugate, ASG-5ME, which targets the solute carrier receptor SLC44A4. SLC44A4 is a member of a family of putative choline transporters that we show to be markedly upregulated in a variet…
View article: Data from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Data from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML Open
CD37 is a tetraspanin expressed on malignant B cells. Recently, CD37 has gained interest as a therapeutic target. We developed AGS67E, an antibody–drug conjugate that targets CD37 for the potential treatment of B/T-cell malignancies. It is…
View article: Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker Open
Details on how the IHC reagent reported in this paper was generated and validated.
View article: Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker Open
SLITRK6 is a member of the SLITRK family of neuronal transmembrane proteins that was discovered as a bladder tumor antigen using suppressive subtractive hybridization. Extensive immunohistochemistry showed SLITRK6 to be expressed in…
View article: Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer Open
Here, we report the development of an antibody–drug conjugate, ASG-5ME, which targets the solute carrier receptor SLC44A4. SLC44A4 is a member of a family of putative choline transporters that we show to be markedly upregulated in a variet…
View article: Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML Open
Figure S1: AGS67E Binds To B-Cells With High Affinity and Induces Cytotoxicity. Figure S2: AGS67E and AGS67C Internalize Into B Cell Lymphma Cells. Figure S3: AGS67E But Not AGS67C Exhibits Anti-Tumor Activity In MOLM-13 Xenografts. Figure…
View article: Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML Open
Figure S1: AGS67E Binds To B-Cells With High Affinity and Induces Cytotoxicity. Figure S2: AGS67E and AGS67C Internalize Into B Cell Lymphma Cells. Figure S3: AGS67E But Not AGS67C Exhibits Anti-Tumor Activity In MOLM-13 Xenografts. Figure…
View article: Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker Open
SLITRK6 is a member of the SLITRK family of neuronal transmembrane proteins that was discovered as a bladder tumor antigen using suppressive subtractive hybridization. Extensive immunohistochemistry showed SLITRK6 to be expressed in…
View article: Data from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Data from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML Open
CD37 is a tetraspanin expressed on malignant B cells. Recently, CD37 has gained interest as a therapeutic target. We developed AGS67E, an antibody–drug conjugate that targets CD37 for the potential treatment of B/T-cell malignancies. It is…
View article: Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer Open
Figure S1. Proteolytic release of MMAE from ASG-5ME; Figure S2. SLC44A4 RNA expression in normal and tumor specimens from combined Oncomine data sets; Figure S3: Expression of SLC44A4 in OVCAR-5 cells determined by FACS.
View article: Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer Open
Figure S1. Proteolytic release of MMAE from ASG-5ME; Figure S2. SLC44A4 RNA expression in normal and tumor specimens from combined Oncomine data sets; Figure S3: Expression of SLC44A4 in OVCAR-5 cells determined by FACS.
View article: Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker Open
Details on how the IHC reagent reported in this paper was generated and validated.
View article: Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 2. Comparability of Anti-ENPP3 ADC Produced in Hybridoma or CHO Cells
View article: Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 2. AGS16-7.8 does not inhibit the enzymatic activity of purified ENPP3.
View article: Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 4. Pharmacokinetics of AGS16F. Mice were injected with a single dose of AGS16F.
View article: Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 4. Pharmacokinetics of AGS16F. Mice were injected with a single dose of AGS16F.
View article: Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 4. Pharmacokinetics of AGS16F. Mice were injected with a single dose of AGS16F.
View article: Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 2. AGS16-7.8 does not inhibit the enzymatic activity of purified ENPP3.
View article: Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 5. Immunostaining for cleaved PARP-1 and PPH3 in tumors.
View article: Supplemental Methods from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Methods from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Methods
View article: Supplemental Table 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 1. Quantification of ENPP3 Expression in Various Carcinomas
View article: Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 2. AGS16-7.8 does not inhibit the enzymatic activity of purified ENPP3.
View article: Supplemental Figure 3A and 3B from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 3A and 3B from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 3A. Mapping of AGS16-7.8 binding to different ENNP3 domains. Supplemental Figure 3B. Western blots for mapping recognition of epitopes in ENPP3 ECD fragments.
View article: Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 2. AGS16-7.8 does not inhibit the enzymatic activity of purified ENPP3.
View article: Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 2. Comparability of Anti-ENPP3 ADC Produced in Hybridoma or CHO Cells
View article: Supplemental Figure 3A and 3B from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 3A and 3B from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 3A. Mapping of AGS16-7.8 binding to different ENNP3 domains. Supplemental Figure 3B. Western blots for mapping recognition of epitopes in ENPP3 ECD fragments.
View article: Supplemental Table 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 1. Quantification of ENPP3 Expression in Various Carcinomas
View article: Supplemental Figure 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 1. AGS16-7.8 and AGS16F do not bind to ENPP1 or ENPP2 proteins.
View article: Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 5. Immunostaining for cleaved PARP-1 and PPH3 in tumors.
View article: Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 2. Comparability of Anti-ENPP3 ADC Produced in Hybridoma or CHO Cells